There’s never been a time when science and technology have formed such a powerful union as they do now. We’re able to identify drug discovery targets using genomics and AI/ML in a way that is unprecedented. We’re also able to use more approaches than ever before to design new medicines and vaccines to address the root cause of disease.
Innovation
Prevention is the best medicine
Prevention is about innovating to change the course of disease
Ahead Together in innovation
We get ahead of disease together by preventing and treating it with innovation in specialty medicines and vaccines. Our R&D approach combines our scientific focus on the immune system - with the use of advanced technologies.
We are working to deliver a new generation of differentiated, needed vaccines and medicines in four core therapeutic areas where we have the strongest expertise, and where significant patient need remains: respiratory, immunology and inflammation; oncology, HIV; and infectious diseases.
Technology powers all aspects of our R&D. We use human genetics and functional genomics, along with artificial intelligence and machine learning (AI/ML), to deeply understand the patient, human biology, and disease mechanisms. This is leading to real breakthroughs for tackling a range of conditions, such as liver disease, or transforming HIV treatment and prevention.
We believe the powerful combination of science and technology holds the key to fundamentally transforming medical discovery for the better, making the R&D process more dynamic, improving success rates and shaping how even the most challenging diseases, like neurological conditions and cancer, can be both prevented and treated.
Medicines and vaccines in development in 2024
71Phase I programmes started in 2024
9
Our pipeline
At GSK, our portfolio and pipeline is focused in developing medicines and vaccines in four core therapeutic areas, which are the areas of human health we focus on to prevent and treat disease: respiratory, immunology and inflammation; oncology; HIV and infectious diseases. We also consider opportunities in organic research and business development in other therapeutic areas, where there is a patient need and where the opportunity fits with our focus on human genetics, genomics, and the science of the immune system.ASSETS
60+
potential vaccines and medicines
FOCUS
>70%
of these assets modulate the immune system
PHASE III
x2
the number of assets in phase III clinical development during the last 5 years
Our therapeutic areas
We prioritise research into new specialty medicines and vaccines, that can prevent and change the course of disease. We focus on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV, and infectious diseases. These are areas where significant patient need remains and where we have the strongest expertise and greatest confidence in our ability to deliver differentiated and needed medicines and vaccines at scale.
We continue to strengthen our pipeline of medicines and vaccines, applying our growing expertise and partnerships in data and technology to increase the productivity of our R&D.
